Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand

Eli Lilly reports strong early demand for its diabetes and weight-loss drug Mounjaro in India, selling over 81,570 units worth 239.4 million rupees ($2.76 million) as of May, with sales rising 60% between April and May. Lilly is focused on meeting this demand amidst rising obesity and diabetes rates in India, where the market for weight-loss drugs is estimated to reach $150 billion by the early 2030s, prompting Indian drugmakers to develop cheaper versions.

Analysis

Eli Lilly's recent introduction of its diabetes and weight-loss drug Mounjaro into the Indian market has demonstrated significant early success, with reported sales exceeding 81,570 units, amounting to approximately 239.4 million rupees ($2.76 million) as of May. This initial uptake is further highlighted by a substantial 60% rise in overall sales between April and May, according to PharmaTrac data. This positive reception occurs within the context of India's large and growing patient population, where government surveys from 2019-2021 indicated that 24% of women and nearly 23% of men aged 15-49 were overweight or obese, and the number of adults with diabetes is projected to surge from 74.2 million in 2021 to over 124 million by 2045. Lilly's strategic advantage of being an early entrant in India, ahead of competitor Novo Nordisk, combined with what PharmaTrac describes as mass-market pricing, positions Mounjaro to potentially become a cornerstone in obesity and diabetes management in the country. Globally, Eli Lilly is proactively addressing the high demand for its GLP-1 agonists by investing over $50 billion since 2020 to scale up production capacity. The Indian market for such drugs is estimated to reach $150 billion by the early 2030s, a lucrative prospect that is also attracting Indian drugmakers who are developing cheaper generic versions, particularly as patents like that for Semaglutide (the active ingredient in Novo Nordisk's Wegovy) are expected to expire in India around 2026. The strongly positive sentiment score of 0.85 for LLY underscores the market's optimistic view of this development.

Key Decisions for Investors

• Investors should recognize Eli Lilly's strong initial market penetration and sales growth for Mounjaro in India as a significant positive development, indicative of substantial demand in a key emerging market with a growing disease burden.
• Consider the long-term growth potential for Lilly stemming from the Indian market, but remain cognizant of Lilly's ongoing efforts to meet global demand through substantial production capacity investments and the eventual emergence of local competition as patents expire.
• Monitor sales trends for Mounjaro in India and Lilly's market share retention, as sustained success will be crucial to capitalizing on the projected $150 billion market opportunity for weight-loss drugs in the region by the early 2030s, especially in light of anticipated generic entries.